Journal of Medicinal Chemistry
Article
(12) Liu, X.-L.; Tee, H.-W.; Go, M.-L. Functionalized chalcones as
selective inhibitors of P-glycoprotein and breast cancer resistance
protein. Bioorg. Med. Chem. 2008, 16, 171−180.
(13) Han, Y.; Riwanto, M.; Go, M.-L.; Ee, P. L. R. Modulation of
breast cancer resistance protein (BCRP/ABCG2) by non-basic
chalcone analogues. Eur. J. Pharm. Sci. 2008, 35, 30−41.
(14) Juvale, K.; Pape, V. F. S.; Wiese, M. Investigation of chalcones
and benzochalcones as inhibitors of breast cancer resistance protein.
Bioorg. Med. Chem. 2012, 20, 346−355.
(15) Boumendjel, A.; McLeer-Florin, A.; Champelovier, P.; Allegro,
D.; Muhammad, D.; Souard, F.; Derouazi, M.; Peyrot, V.; Toussaint,
B.; Boutonnat, J. A novel chalcone derivative which acts as a
microtubule depolymerising agent and an inhibitor of P-gp and BCRP
in in-vitro glioblastoma models. BMC Cancer 2009, 9, 242.
(16) Rabindran, S. K.; He, H.; Singh, M.; Brown, E.; Collins, K. I.;
Annable, T.; Greenberger, L. M. Reversal of a novel multidrug
resistance mechanism in human colon carcinoma cells by fumitre-
morgin C. Cancer Res. 1998, 58, 5850−5858.
(29) Robey, R. W.; Honjo, Y.; Van de Laar, A.; Miyake, A.; Regis, J.
T.; Litman, T.; Bates, S. E. A functional assay for detection of the
mitoxantrone resistance protein, MXR (ABCG2). Biochim. Biophys.
Acta: Biomembranes 2001, 1512, 171−182.
(30) Mosmann, T. Rapid colorimetric assay for cellular growth and
survival. Application to proliferation and cyto-toxicity assays. J.
Immunol. Methods 1983, 65, 55−63.
(31) SYBYL-X 1.3, Tripos International, St. Louis, MO 63144, USA.
(32) Halgren, T. A. MMFF VII. Characterization of MMFF94,
MMFF94s, and other widely available force fields for conformational
energies and for intermolecular-interaction energies and geometries. J.
Comput. Chem. 1999, 7, 730−748.
(33) Cramer, R. D., III; DePriest, S. A.; Patterson, D. E.; Hecht, P.
The Developing Practice of Comparative Molecular Field Analysis in 3D
QSAR in Drug Design: Theory, Methods and Applications; ESCOM:
Leiden, The Netherlands, 1993.
(34) Picard, R.; Cook, D. Cross-validation of regression models. J.
Am. Stat. Assoc. 1984, 79, 575−583.
(17) van Loevezijn, A.; Allen, J. D.; Schinkel, A. H.; Koomen, G. J.
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type
indolyl diketopiperazines. Bioorg. Med. Chem. Lett. 2001, 11, 29−32.
(18) Allen, J. D.; van Loevezijn, A.; Lakhai, J. M.; van der Valk, M.;
van Tellingen, O.; Reid, G.; Schellens, J. H. M.; Koomen, G. J.;
Schinkel, A. H. Potent and specific inhibition of the breast cancer
resistance protein multidrug transporter in vitro and in mouse
intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther.
2002, 1, 417−425.
(19) Boumendjel, A.; Boccard, J.; Carrupt, P.-A.; Nicolle, E.; Blanc,
M.; Geze, A.; Choisnard, L.; Wouessidjewe, D.; Matera, E. L.;
Dumontet, C. Antimitotic and antiproliferative activities of chalcones:
forward structure-activity relationship. J. Med. Chem. 2008, 51, 2307−
2310.
(20) Martel-Frachet, V.; Kadri, M.; Boumendjel, A.; Ronot, X.
Structural requirement of arylindolylpropenones as anti-bladder
carcinoma cells agents. Bioorg. Med. Chem. 2011, 19, 6143−6148.
(21) Harborne, J. B.; Williams, C. A. Advances in flavonoid research
since 1992. Phytochemistry 2000, 55, 481−504.
(22) Kachadourian, R.; Day, B. J.; Pugazhenti, S.; Franklin, C. C.;
Genoux-Bastide, E.; Mahaffey, G.; Gauthier, C.; Di Pietro, A.;
Boumendjel, A. A synthetic chalcone as a potent inducer of glutathione
biosynthesis. J. Med. Chem. 2012, 55, 1382−1388.
(23) Valdameri, G.; Genoux-Bastide, E.; Peres, B.; Gauthier, C.;
Guitton, J.; Terreux, R.; Winnischofer, S. M. B.; Rocha, M. E. M.;
Boumendjel, A.; Di Pietro, A. Substituted chromones as highly-potent,
nontoxic inhibitors, specific for the breast cancer resistance protein
ABCG2. J. Med. Chem. 2012, 55, 966−970.
(24) Valdameri, G.; Pereira Rangel, L.; Sapatafora, C.; Guitton, J.;
Gauthier, C.; Arnaud, O.; Ferreira-Pereira, A.; Falson, P.;
Winnischofer, S. M. B.; Rocha, M. E. M.; Tringali, C.; Di Pietro, A.
Methoxy stilbenes as potent, specific, untransported and noncytotoxic
inhibitors of breast cancer resistance protein. ACS Chem. Biol. 2012, 7,
322−330.
(25) Boumendjel, A.; Di Pietro, A.; Dumontet, C.; Barron, D. Recent
advances in the discovery of flavonoids and analogs with high-affinity
binding to P-gp responsible for cancer cell multidrug resistance. Med.
Res. Rev. 2002, 22, 512−529.
(26) Macalou, S.; Ahmed-Belkacem, A.; Borelli, F.; Capasso, R.;
Fattorusso, E.; Taglialatela-Scafati, O.; Di Pietro, A. Non-prenylated
rotenoids, a new class of potent breast cancer resistance protein
inhibitors. J. Med. Chem. 2007, 50, 1933−1938.
(27) Boumendjel, A.; Macalou, S.; Ahmed-Belkacem, A.; Blanc, M.;
Di Pietro, A. Acridone derivatives: design, synthesis, and inhibition of
breast cancer resistance protein ABCG2. Bioorg. Med. Chem. 2007, 15,
2892−2897.
̀
(28) Arnaud, O.; Boumendjel, A.; Geze, A.; Honorat, M.; Matera, E.
L.; Guitton, J.; Stein, W. D.; Bates, S. E.; Falson, P.; Dumontet, C.; Di
Pietro, A.; Payen, L. The acridone derivative MBLI-87 sensitizes breast
cancer resistance protein-expressing xenografts to irinotecan. Eur. J.
Cancer 2011, 47, 640−648.
3200
dx.doi.org/10.1021/jm2016528 | J. Med. Chem. 2012, 55, 3193−3200